The fear for shareholders is that a delay could mean that mRNA-1345 won’t be ready to roll out in the US in time for the ...
The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA-1345, ...
Moderna stock skidded Friday after the FDA delayed an approval decision on its RSV vaccine until the end of the month.
(RTTNews) - Moderna, Inc. (MRNA) announced Friday that the U.S. Food and Drug Administration's review of the Biologics License Application or BLA for mRNA-1345, its investigational respiratory ...
The FDA hasn't informed Moderna of any issues related to vaccine safety, efficacy or quality that would prevent approval, ...
The Food and Drug Administration (FDA) notified Moderna Inc (NASDAQ:MRNA) on Friday that its review of a new vaccine has been ...
Moderna reported better-than-expected 1Q24 revenue of $167 million and its pipeline looks promising. Read my earnings ...
By Colin Kellaher Moderna on Friday said the Food and Drug Administration won't meet its May 12 target action date for a decision on the company's ...
The FDA has delayed a key meeting to determine the formula for the next COVID-19 vaccines amid a spike in cases linked to the ...
Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has ...
First, a bit of background on Moderna's RSV candidate. RSV generally causes cold-like symptoms, but the virus could be severe ...
Respiratory syncytial virus (RSV) remains a major cause of life-threatening respiratory illness in older adults. Estimates ...